Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Oxytrol Medicaid Reimbursement Expected In 75% Of States At Launch

  • News

Executive Summary

Watson expects almost three-quarters of state Medicaid plans to cover its Oxytrol overactive bladder patch immediately upon launch in May

You may also be interested in...



Watson Oxytrol Launch Focus On Heavy Sampling Has Delayed Rx Uptake

Watson's launch for its Oxytrol overactive bladder patch is relying on heavy sampling, the company said during its second quarter investor call Aug. 5

Watson Oxytrol Launch Focus On Heavy Sampling Has Delayed Rx Uptake

Watson's launch for its Oxytrol overactive bladder patch is relying on heavy sampling, the company said during its second quarter investor call Aug. 5

Pfizer/Pharmacia Clears FTC: Viagra Patent Strategy, HRT Safety Are Factors

Pfizer's patent defense strategy for Viagra is one reason the Federal Trade Commission is requiring the divestiture of Phase II erectile dysfunction disorder agents as a condition of the Pfizer/Pharmacia merger

Table

View full table

Related Content

Pink Sheet
Tags:
Latest Headlines

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

Partisan Politics Returns To US FDA Congressional Oversight

GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows

Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development

See All
UsernamePublicRestriction

Register

PS041535

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By